REGN•benzinga•
Sanofi And Regeneron To Consult Regulators After Mixed Phase 3 COPD Results For Itepekimab, As AERIFY-1 Meets Primary Endpoint And AERIFY-2 Falls Short
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 30, 2025 by benzinga